These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 19085118

  • 1. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs.
    Zhang C, Newsome JT, Mewani R, Pei J, Gokhale PC, Kasid UN.
    Methods Mol Biol; 2009; 480():65-83. PubMed ID: 19085118
    [Abstract] [Full Text] [Related]

  • 2. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C, Pei J, Kumar D, Sakabe I, Boudreau HE, Gokhale PC, Kasid UN.
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
    Gokhale PC, Zhang C, Newsome JT, Pei J, Ahmad I, Rahman A, Dritschilo A, Kasid UN.
    Clin Cancer Res; 2002 Nov; 8(11):3611-21. PubMed ID: 12429653
    [Abstract] [Full Text] [Related]

  • 4. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR, Tang W, Rahman A, Dritschilo A, Ahmad I, Kasid UN, Gokhale PC.
    Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
    [Abstract] [Full Text] [Related]

  • 5. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.
    Garbuzenko OB, Saad M, Betigeri S, Zhang M, Vetcher AA, Soldatenkov VA, Reimer DC, Pozharov VP, Minko T.
    Pharm Res; 2009 Feb; 26(2):382-94. PubMed ID: 18958402
    [Abstract] [Full Text] [Related]

  • 6. Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine.
    Pei J, Zhang C, Gokhale PC, Rahman A, Dritschilo A, Ahmad I, Kasid UN.
    Anticancer Drugs; 2004 Mar; 15(3):243-53. PubMed ID: 15014358
    [Abstract] [Full Text] [Related]

  • 7. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
    Pirollo KF, Rait A, Zhou Q, Hwang SH, Dagata JA, Zon G, Hogrefe RI, Palchik G, Chang EH.
    Cancer Res; 2007 Apr 01; 67(7):2938-43. PubMed ID: 17409398
    [Abstract] [Full Text] [Related]

  • 8. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer.
    Pal A, Ahmad A, Khan S, Sakabe I, Zhang C, Kasid UN, Ahmad I.
    Int J Oncol; 2005 Apr 01; 26(4):1087-91. PubMed ID: 15754006
    [Abstract] [Full Text] [Related]

  • 9. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis.
    Andreakos E, Rauchhaus U, Stavropoulos A, Endert G, Wendisch V, Benahmed AS, Giaglis S, Karras J, Lee S, Gaus H, Bennett CF, Williams RO, Sideras P, Panzner S.
    Arthritis Rheum; 2009 Apr 01; 60(4):994-1005. PubMed ID: 19333921
    [Abstract] [Full Text] [Related]

  • 10. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.
    Senn C, Hangartner C, Moes S, Guerini D, Hofbauer KG.
    Eur J Pharmacol; 2005 Oct 17; 522(1-3):30-7. PubMed ID: 16213482
    [Abstract] [Full Text] [Related]

  • 11. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes.
    Sonoke S, Ueda T, Fujiwara K, Sato Y, Takagaki K, Hirabayashi K, Ohgi T, Yano J.
    Cancer Res; 2008 Nov 01; 68(21):8843-51. PubMed ID: 18974128
    [Abstract] [Full Text] [Related]

  • 12. RAF antisense oligonucleotide as a tumor radiosensitizer.
    Kasid U, Dritschilo A.
    Oncogene; 2003 Sep 01; 22(37):5876-84. PubMed ID: 12947394
    [Abstract] [Full Text] [Related]

  • 13. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
    Yang XZ, Dou S, Sun TM, Mao CQ, Wang HX, Wang J.
    J Control Release; 2011 Dec 10; 156(2):203-11. PubMed ID: 21839126
    [Abstract] [Full Text] [Related]

  • 14. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S.
    J Drug Target; 2009 Aug 10; 17(7):491-5. PubMed ID: 19530907
    [Abstract] [Full Text] [Related]

  • 15. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer.
    Gokhale PC, Soldatenkov V, Wang FH, Rahman A, Dritschilo A, Kasid U.
    Gene Ther; 1997 Dec 10; 4(12):1289-99. PubMed ID: 9472552
    [Abstract] [Full Text] [Related]

  • 16. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
    Zhang Y, Ma Y, Lu HP, Zhou XF, Xie Y, Gao JH, Liang CS.
    Zhonghua Yi Xue Za Zhi; 2008 Jul 29; 88(29):2073-6. PubMed ID: 19080439
    [Abstract] [Full Text] [Related]

  • 17. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
    Li SD, Huang L.
    Mol Pharm; 2006 Jul 29; 3(5):579-88. PubMed ID: 17009857
    [Abstract] [Full Text] [Related]

  • 18. Liposome-coated lipoplex-based carrier for antisense oligonucleotides.
    Wyrozumska P, Meissner J, Toporkiewicz M, Szarawarska M, Kuliczkowski K, Ugorski M, Walasek MA, Sikorski AF.
    Cancer Biol Ther; 2015 Jul 29; 16(1):66-76. PubMed ID: 25482931
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer.
    Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I, Naito H, Kitagawa H, Ishiyama K, Ohgi T, Irimura T.
    Clin Cancer Res; 2004 Nov 15; 10(22):7721-6. PubMed ID: 15570006
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.